AlphaMadera's AlphaVal page computes Cushman & Wakefield plc's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag CWK as undervalued, fairly valued, or overvalued.

What is Cushman & Wakefield plc's fair value?

Fair value for CWK is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value CWK?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from CWK's most recent reported fundamentals.

CWK - Cushman & Wakefield plc

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $18.40 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 75% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Mild

Trading 14.0% above fair value

Current Price $12.89

Bear Case $9.04 29.9% downside ($9.04 - $12.89) / $12.89 = -29.9% $0.60 × 12x P/E

Fair Value $11.30 12.3% downside ($11.30 - $12.89) / $12.89 = -12.3% $0.60 × 15x P/E

Bull Case $13.56 5.2% upside ($13.56 - $12.89) / $12.89 = 5.2% $0.60 × 18x P/E

Adjust Assumptions

P/E Multiple

15.0x

Adjusted EPS

0.6$

Key Value Driver

Normalized P/E multiple (15x base case)

Implied Market Multiple 21.6x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $18.40 from 16 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $11.30 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 57%. Check what costs are being left out of the adjusted number.

ℹ Wall Street's average price target is $18.40 (from 16 analysts). Our estimate is 51% below the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples